
Spero Therapeutics (SPRO) Stock Forecast & Price Target
Spero Therapeutics (SPRO) Analyst Ratings
Bulls say
Spero Therapeutics is positive on the stock because its newly in-licensed SP001 creates a clearer, higher-quality long-term value driver than the prior tebipenem-centric story, with a $35M upfront payment and a total deal value of about $1.05B in potential milestones plus royalties. The case is strengthened by SP001’s differentiated Fc-silent anti-CD40L design, which targets upstream B- and T-cell activation in IgG4-RD while aiming to avoid the thromboembolic issues that limited earlier CD40L antibodies, and by encouraging Phase 1b safety and efficacy signals in Sjögren’s disease. Financially, the stock also benefits from a $105M non-dilutive royalty financing, a runway into 2H29, and a valuation framework that assigns roughly $310M to SP001 rNPV with upside supported by a Phase 2 start in 2Q27 and the potential for broader inflammatory indications.
Bears say
Spero Therapeutics is a high-risk clinical-stage company whose outlook is weakened by repeated development setbacks, most notably the 2024 interim analysis showing that the Phase 2a proof-of-concept study of SPR720 missed its primary endpoint. That failure forced significant restructuring to extend cash runway only into mid-2026, underscoring continued dependence on external financing or partnerships to fund development and eventual commercialization. Beyond the balance-sheet pressure, the company still faces major clinical, regulatory, and competitive uncertainty across its pipeline, and any future efficacy or safety shortfall could further impair approval prospects and investor confidence.
This aggregate rating is based on analysts' research of Spero Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Spero Therapeutics (SPRO) Analyst Forecast & Price Prediction
Start investing in Spero Therapeutics (SPRO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Spero Therapeutics (SPRO) Forecast
Spero Therapeutics (SPRO) Analyst Forecast & Price Prediction
Start investing in Spero Therapeutics (SPRO)
Order type
Buy in
Order amount
Est. shares
0 shares